INFLECTRA

Manufacturer:

Pfizer

Name:

INFLECTRA

HCPCS Code Descriptor:

Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg

Category:

Q Code

HCPCS:

Q5103

NDC(s):

00069-0809-01

Primary Type:

Immunology Anti-TNF Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

INFLECTRA is an Immunology Anti-TNF Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5103 is aligned to the drug INFLECTRA.

Inflectra (infliximab) is a monoclonal antibody and is used to treat a range of inflammatory autoimmune disorders. Inflectra binds to tumor necrosis factor-alpha and prevents it from activating certain processes. This drug is administered via a 2-hour intravenous infusion. Inflectra is manufactured by Pfizer and is a biosimilar to Remicade (J1745). Inflectra was aligned to the Q Code: Q5102 until March 2018, when it was realigned to the Q Code: Q5103. Patient Assistance can be found through the Pfizer EnCompass program.